Losartan Dosing in Renal Impairment: Evidence-Based Guidelines for Kidney Disease

Published May 26, 2026Updated Sep 30, 2026Last reviewed May 26, 2026

7 linked public sourcesEditorial, sourcing, and corrections policy

Reduced kidney function alone does not require a losartan dose reduction. The usual adult starting dose is 50 mg once daily, with adjustment according to blood pressure and tolerability. Volume depletion and mild-to-moderate liver impairment can call for a 25 mg starting dose. [1]

The key follow-up measurements are blood pressure, potassium and creatinine. Together, they show whether the treatment is achieving its purpose and whether the dose remains appropriate.

Dosing in chronic kidney disease

Situation	Dosing consideration
Stable adult with CKD	No automatic reduction for renal impairment alone
Volume depletion, including with substantial diuretic use	Consider 25 mg initially
Mild-to-moderate hepatic impairment	Recommended starting dose: 25 mg daily
Hypertension or the labeled diabetic-nephropathy indication	Usual starting dose: 50 mg daily; may increase to 100 mg
Hemodialysis	Neither losartan nor its active metabolite is removed by dialysis

These points come from Cozaar prescribing information. They do not make 50 mg the right starting dose for every dialysis patient. Blood pressure, volume status and the existing regimen remain part of the prescribing decision. [1]

Why losartan is used for kidney protection

The RENAAL trial enrolled 1,513 people with type 2 diabetes and nephropathy. Participants received losartan 50 to 100 mg daily or placebo in addition to other blood-pressure treatment, with an average follow-up of 3.4 years. [2]

Losartan reduced the relative risk of the combined primary outcome, doubling of serum creatinine, end-stage kidney disease or death, by 16%. The individual relative risk reductions were 25% for doubling of creatinine and 28% for end-stage kidney disease; mortality itself was unchanged. The kidney benefit exceeded what could be explained by the blood-pressure difference alone. [2]

These findings apply to the population studied. They support losartan's role in diabetic nephropathy and help explain why an early laboratory change deserves interpretation rather than an automatic assumption that the medicine is harming the kidneys.

When to check potassium and creatinine

KDIGO's 2024 CKD guideline recommends checking blood pressure, serum creatinine and potassium within two to four weeks after starting or increasing an ACE inhibitor or ARB. The timing within that plan depends on kidney function and potassium; higher-risk situations can require earlier assessment. Use the highest approved dose that is tolerated when pursuing the benefits established in trials. [3]

Ask for the follow-up plan when the prescription changes:

Which day should I have the blood test?
Who will review the result and contact me?
Which blood-pressure readings should I record?
Has anything changed in my diuretics, pain medicines, supplements or salt substitutes?

Keep both the baseline and follow-up results. A single number without its previous value can be harder to interpret.

What does a creatinine increase mean?

An early rise can follow a change in kidney filtration pressure. KDIGO advises continuing ACE-inhibitor or ARB treatment unless creatinine rises by more than 30% within four weeks of starting or increasing the dose. A larger rise calls for evaluation, including volume depletion and interacting medicines. [3]

For example, a change from 1.5 to 1.8 mg/dL is a 20% increase. A change from 1.5 to 2.1 mg/dL is a 40% increase. This calculation helps frame the conversation; the clinician also needs the potassium result, symptoms and timing.

Should losartan be stopped below an eGFR of 30?

A low eGFR alone is not a reason to stop a tolerated ARB. KDIGO supports continuation below 30 mL/min/1.73 m². Dose reduction or discontinuation may become appropriate with symptomatic hypotension, potassium that remains uncontrolled despite treatment, or selected circumstances in kidney failure. [3]

STOP-ACEi tested stopping versus continuing renin-angiotensin-system inhibitors in 411 people with advanced progressive CKD. At three years, average eGFR was 12.6 in the discontinuation group and 13.3 in the continuation group, without a significant difference. Stopping did not improve long-term kidney function. This was a drug-class trial, not a losartan-only trial. [4]

Why combining losartan with an ACE inhibitor is different

VA NEPHRON-D assigned 1,448 people with diabetic nephropathy, already receiving losartan, to lisinopril or placebo. The study stopped early because of safety concerns. Adding lisinopril increased hyperkalemia and acute kidney injury without a significant improvement in the primary kidney-and-death outcome. [5]

The practical implication is to review the complete medication list before adding another blood-pressure drug. More blockade of the same system does not automatically provide more kidney protection.

What if you also have gout?

The American College of Rheumatology conditionally recommends choosing losartan preferentially as an antihypertensive for patients with gout when feasible. This can help guide a choice between otherwise suitable blood-pressure medicines. It does not replace a urate-lowering treatment plan when that treatment is indicated. [6]

Kidney clearance and existing precautions

Losartan has an active metabolite, but the parent drug is also active. Drug exposure can increase with renal impairment, even though the label does not require routine renal dose adjustment. This is why the absence of a dose-reduction table should not be confused with an absence of monitoring. [1]

If pregnancy is detected, stop losartan promptly and contact the prescriber for an alternative. Seek urgent care for face or throat swelling, breathing difficulty, fainting, marked muscle weakness with palpitations, or sharply reduced urine output. [1,7]

References

Evidence overview for Losartan Dosing in Renal Impairment: Evidence-Based Guidelines for Kidney Disease